Phase 2 Trial: SHR-1701 Plus Chemoradiotherapy for Advanced Rectal Cancer
Could a new drug boost treatment for severe colorectal cancer?
A Phase 2 trial is recruiting to evaluate SHR-1701 with chemoradiotherapy in severe CRC. Primary outcome is pCR.
A new drug combined with standard chemo and radiation aims to clear severe colorectal cancer before surgery in an upcoming trial.
Phase II Study on SHR-8068 Injection in Colorectal Cancer Now Recruiting
Could a new treatment help fight colorectal cancer more effectively?
A Phase II trial is recruiting to assess SHR-8068 with Adebrelimab and Bevacizumab in colorectal cancer for pCR and PFS.
A new drug combo for colorectal cancer is being tested in 200 patients to see if it improves survival and tumor response.
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
High Dietary Inflammatory Index Linked to Increased NAFLD Risk (OR 1.33, CI 1.23-1.44)
Could Your Diet Be Fueling Fatty Liver Disease?
Meta-analysis of 262,468 participants shows high Dietary Inflammatory Index (DII) significantly increases risk of NAFLD (OR 1.33, 95% CI: 1.…
A high-inflammation diet is strongly linked to fatty liver disease and liver scarring in a review of over 262,000 people.